DBV Technologies announced the following changes to its leadership team as the Company strengthens its organizational competencies in the development of the Viaskin platform: DBV's Chief Scientific Officer (CSO), Dr. Hugh Sampson, will also assume the role of interim Chief Medical Officer (CMO) effective January 3, 2019. Dr. Sampson succeeds Dr. Lucia Septien-Velez, who has decided to leave to pursue other opportunities. As CSO and interim CMO, Dr. Sampson will lead both the scientific and medical teams at the Company and will report to Daniel Tassé, Chief Executive Officer of DBV Technologies. Dr. Sampson is an accomplished leader and physician, and his research and scientific advancements have had a significant influence in the field of food allergies and immunology over the last 40 years. Following recent interactions with the U.S. Food and Drug Administration (FDA), global manufacturing industry leader, Julie O'Neill, has been engaged effective immediately to direct all product development, manufacturing, supply chain, quality assurance, and end-to-end process optimization at the Company. She brings over 30 years of experience in global manufacturing to DBV, where she will directly advise Daniel Tassé. Julie, who was appointed to DBV's Board of Directors in 2017, will continue serving as a director, while overseeing the anticipated resubmission of the Viaskin Peanut Biologics License Application (BLA) in children four to 11 years of age. Most recently, Julie was Executive Vice President, Global Operations for Alexion Pharmaceuticals Inc. As part of these operational changes announced January 3, 2019, Alan Kerr, Senior Vice President, Head of Global Regulatory Affairs of DBV Technologies, will now report to the Company's CEO, Daniel Tassé, effective immediately. Effective January 3, 2019, Dr. Sampson will lead both scientific and medical efforts at the Company. In collaboration with the Company's regulatory experts, Dr. Sampson will also support regulatory submissions for Viaskin Peanut, while continuing to drive scientific innovation of the Company's proprietary technology platform, Viaskin. DBV has launched a search for a permanent CMO based in the United States. Dr. Sampson was appointed CSO of DBV Technologies in June 2015 and is a member of the Company's Executive Committee and Scientific Advisory Board. He is also the Kurt Hirschhorn Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai and Director Emeritus of the Jaffe Food Allergy Institute.